Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Ltd. (NASDAQ: TLX) securities.
If you suffered a loss on your Telix Pharmaceuticals Ltd. investment and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: Feb 21 2025 - Aug 28 2025
CASE DETAILS: The filed complaint alleges that Telix Pharmaceuticals Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) defendants materially overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants’ statements about Telix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks.
We monitor critical case developments that may affect the price of your shares and your possible monetary recovery.
SnapTrade only shares the tickers you own and your transaction history — not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create an attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery — link your brokerage account with SnapTrade.